Can Indian biosimilars and generics restate accessibility in global underserved markets?
Pharmacy of the world, a name that India has earned through the provision of low-cost, quality generics to patients…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
generics
The R&D playbook for complex generics
Dr Rakesh Bhasin, Head R&D (Formulations), Biocon, gave a presentation on 'The R&D playbook for complex generics'. He…
Indian pharma industry profitability improves as pricing environment eases: Equirus Capital
Trade generics and Jan Aushadhi are steadily gaining volume share from branded formulations, especially in price-sensitive acute…
Big Pharma prepare for next patent cliff as blockbuster drugs revenue losses loom: GlobalData
According to GlobalData’s latest report, there is set to be a smaller proportion of global drug sales which will have patent…
IGBA releases first global Intellectual Property and Competition Report
IGBA report outlines market practices delaying access to generic and biosimilar medicines
Yugal Sikri outlines 3 key trends defining India’s pharma growth in 2025
Market consolidation, AI-driven innovation, and supportive government policies are set to propel India's pharma industry toward…
Challenges in procurement of “Quality Assured” generics
Dr Suresh Saravdekar, Ex-Assistant Director, Ministry of Medical Education and Health, State of Maharashtra and Ex-honorary…
New study shows novel strategy to improve quality checking of generic drugs
The strategy is likely to improve the regulatory and decision-making aspects related to pharmaceutical products
Pfizer to allow generic COVID pill in 95 countries
There is no patent yet on the experimental candidate PF-07321332, and ritonavir has been off-patent since last year
Biocon expands its generic formulations, launches Everolimus tablets in US
Everolimus (Afinitor) is a prescription medication that is used to treat certain types of cancers and tumours